Page 151 - CW E-Magazine (4-2-2025)

Pharmaceuticals

INVESTING IN INFRASTRUCTURE
Emcure Pharma opens formulation R&D centre

in Gujarat

Pune-based Emcure Pharmaceuti- research and one facility
cals, has inaugurated its new formula- on biopharmaceuticals
tion R&D Centre near Tapovan Circle, research. The company
Ahmedabad. The Emcure Research operates around 13 manu-
Centre (ERC) is designed to enable facturing facilities in
breakthroughs in complex drug deli- the country of which
very systems, such as sustained-release the units at Jammu,
formulations, liposomal injections and Sikkim and Bengaluru
advanced dermal therapies. serve the domestic mar-
ket. “Though we started
The new facility seeks to seamlessly “This new R&D centre represents a from Maharashtra, our manufacturing
integrates all aspects of pharmaceuti- signifi cant milestone in our continued capacities in Gujarat have exceeded
cal development right from early-stage pursuit of innovation, by combining Maharashtra. We have a facility for
pre-formulation studies to scaling-up. advanced research technology with a injectables in Sanand (near Ahmedabad)
A team of 350 professionals, including talented team. It centre will drive from where we export to Europe, US
doctorate, post-graduate and graduate research across multiple dosage forms, and emerging markets. We have a facility
specialising in pharmaceutical sciences, including OSD, injectables, novel drug for tablets at Kadu near Surendranagar
bio-engineering, analytical chemistry, delivery systems (NDDS), inhalers and which is also focussed on exports. We
pharmacovigilance and regulatory topical and transdermal formulations,” have a third facility for tablets and
affairs will work together to develop said Mr. Satish Mehta, Founder and injectables at Mehsana which serves
novel formulations, enhance drug bio- CEO, Emcure Pharmaceuticals Of the both the export and domestic markets.
availability and create patient-centric company’s fi ve R&D facilities, three This facility exports to Europe, Canada
delivery solutions, the company in- facilities are focused on formulations and emerging markets,” Mr. Mehta
formed. research, one facility focused on API informed.

TPG Scion’s stake acquisition in Schott Poonawalla

awaits CCI nod

US private equity fi rm, TPG involves an equity acquisition, mark-
Group’s affi liate, TPG Scion SG Pte ing a strategic entry of TPG into the
Ltd.’s bid to acquire a stake in Schott growing pharmaceutical packaging
Poonawalla Pvt. Ltd. (SPPL). is cur- sector. TPG Scion, a special purpose
rently being reviewed by the Compe- investment vehicle incorporated in
tition Commission of India (CCI) for Singapore in October 2024, is backed
regulatory approval. by the TPG Group. Although TPG
Scion currently has no operations in
Mumbai-headquartered Schott India, this move signals a targeted in-
Poonawalla is a leading primary glass vestment in the country’s expanding
packaging provider for the pharma year, it was reported that SII had held pharmaceutical ecosystem.
and biotech sectors and a 50:50 joint discussions with TPG to sell 40%
venture between Pube-based Serum stake held by the top vaccine maker According to the submission to
Institute of India (SII) and Schott in Schott Poonawalla. The proposed CCI, the parties believe that the deal
Pharma, which is part of German transaction, categorised under Section will not raise competition concerns in
speciality glass fi rm Schott AG. Last 5(d) of the Competition Act, 2002, the Indian market.

Chemical Weekly February 4, 2025 151

Contents Index to Advertisers Index to Products Advertised